Superoxide dismutase 2 (SOD2), also known as manganese-dependent superoxide dismutase (MnSOD), is a mitochondrial antioxidant enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen, protecting cells from oxidative damage. SOD2 plays a critical role in maintaining redox balance and mitochondrial function, with implications in aging, inflammation, and various diseases. Antibodies targeting SOD2 are essential tools for detecting its expression, localization, and regulation in biological systems.
SOD2 antibodies are widely used in research to study oxidative stress-related pathologies, including cancer, neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s), cardiovascular diseases, and diabetes. They enable techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to quantify SOD2 levels in tissues or cultured cells. These antibodies help elucidate SOD2's dual role in cancer—acting as a tumor suppressor in early stages but potentially promoting metastasis in advanced malignancies.
Commercial SOD2 antibodies are typically raised against specific epitopes of human or murine SOD2. with validations across species and applications. Researchers prioritize antibodies with high specificity, minimal cross-reactivity (e.g., with SOD1 or SOD3), and compatibility with formalin-fixed or frozen samples. Recent studies also explore SOD2's involvement in metabolic reprogramming and immune modulation, expanding its relevance in therapeutic targeting. Understanding SOD2 dynamics through antibody-based assays remains pivotal for advancing antioxidant therapies and precision medicine.